by Novadip | Feb 20, 2025 | Press Releases, Featured News
At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union No adverse events related to NVDX3 observed A phase 2b/3 trial in 2-level cervical spine...
by Novadip | Jan 31, 2025 | Press Releases
88% efficacy demonstrated across all patients (n=17) treated withNVD003 to date (nine adults with bone non-union and eight childrenwith Congenital Pseudarthrosis of the Tibia)100% efficacy demonstrated when mechanical stability of fracture isachievedCompany now...
by Novadip | Jan 30, 2025 | Press Releases
Seasoned financial executive with over 30 years’ experience -including senior management of orthopedic startups – to supportNovadip in its financing rounds and expansion into US orthopedicsmarket Mont Saint-Guibert, Belgium, January 9, 2025 – Novadip...
by Novadip | Nov 22, 2024 | Press Releases
Built upon robust preclinical and clinical datasets, NVDX3 has potential to replace existing allogenic bone grafting materials – providing patients with complex comorbidities better bone fusion success Phase 2b/3 expected to begin enrollment in H2 2025 in the US...
by Novadip | Oct 24, 2024 | Press Releases
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix...